A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)

StatusRecruiting
PhasePhase 4
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites: 40 to 39v20
  2. Study sites: 41 to 40v19
  3. Study sites: 43 to 41v18
  4. Study sites revised (43)v17
  5. Study sites: 44 to 43v16
Show 14 earlier versionsHide 14 earlier versions
  1. Study sites: 45 to 44v15
  2. Primary and study completion dates: Oct 2026 to May 2028
    • Site details revised at 1 of 45 sites
    v14
  3. Site details revised at 3 of 45 sitesv13
  4. Site details revised at 1 of 45 sitesv12
  5. Site details revised at 1 of 45 sitesv11
  6. Study sites: 42 to 45v10
  7. Study sites: 39 to 42v9
  8. Study sites: 40 to 39v8
  9. Site details revised at 3 of 40 sitesv7
  10. Study sites: 41 to 40v6
  11. Study sites: 39 to 41v5
  12. Study sites: 37 to 39v4
  13. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 13 to 37
    • Start date changed from estimate of Mar 2025 to Mar 19, 2025
    v3
  14. Secondary endpoints revised (7)
    • Study title expanded, about 2 words
    v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Eli Lilly
365 trials monitored
See 16 trials at risk
Obesity
3,898 trials monitored
See 160 trials at risk
Psoriasis
596 trials monitored
See 24 trials at risk
The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe plaque PsO and obesity or overweight with at least 1 weight-related comorbidity. The study will last up to 12 months.
Trial Details
NCT Number NCT06857942
Lead Sponsor Eli Lilly and Company
Conditions
(from sponsor)		 Psoriasis, Overweight or Obesity
Related terms Obesity, Overweight, Psoriasis
Enrollment 200 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov